Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRN | P28799 | 7/20 | 0.50 |
| ▸ | SORT1 | Q99523 | 7/20 | 0.50 |
| ▸ | TAS1R3 | Q7RTX0 | 2/20 | 0.49 |
| ▸ | TAS1R1 | Q7RTX1 | 2/20 | 0.49 |
| ▸ | RECQL | P46063 | 1/20 | 0.46 |
| ▸ | KDR | P35968 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 2/20 | 0.43 |
| ▸ | ACLY | P53396 | 1/20 | 0.43 |
| ▸ | MLYCD | O95822 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | GPR139 | Q6DWJ6 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1829148 | 0.89 | GRN (0.60) | GRNSORT1RECQLHPGDACLY | |
| SCHEMBL26454584 | 0.87 | TAS1R3 (0.56) | TAS1R3TAS1R1HPGDMLYCDALOX15 | |
| SCHEMBL14275080 | 0.87 | TAS1R3 (0.60) | TAS1R3TAS1R1HPGDMLYCDALOX15 | |
| Acetic Acid SCHEMBL11295237 | 0.81 | TAS1R3 (0.55) | TAS1R3TAS1R1HPGDMLYCDALOX15 | |
| SCHEMBL23984461 | 0.81 | TAS1R3 (0.54) | GRNSORT1TAS1R3TAS1R1RECQL | |
| SCHEMBL6173135 | 0.80 | TPMT (0.57) | TAS1R3TAS1R1HPGDMLYCDNPSR1 | |
| SCHEMBL9926545 | 0.79 | KDR (0.47) | GRNSORT1KDRHPGD | |
| SCHEMBL13485819 | 0.79 | HDAC6 (0.53) | KDR | |
| SCHEMBL30518015 | 0.79 | KDR (0.47) | GRNSORT1KDRHPGD | |
| SCHEMBL12688285 | 0.79 | TAS1R3 (0.53) | TAS1R3TAS1R1HPGDMLYCDNPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240208968-A1 | ALPHA V BETA 6 AND ALPHA V BETA 1 INTEGRIN INHIBITORS AND USES THEREOF | DICE MOLECULES SV, INC. | 2024-06-27 | — | — | US | disclosed |
| US-20170333406-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2017-11-23 | — | — | US | disclosed |
| US-9763922-B2 | Therapeutic compounds and uses thereof | GENENTECH, INC. (US) | 2017-09-19 | — | — | US | disclosed |
| US-20160158207-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2016-06-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170333406-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | EP300, HDAC1, HDAC10 | GRN 1643/4885SORT1 2654/4885TAS1R3 3503/4885 |
| US-20240208968-A1 | ALPHA V BETA 6 AND ALPHA V BETA 1 INTEGRIN INHIBITORS AND USES THEREOF | ITGB1, ITGA1, ITGAV | GRN 4112/4885SORT1 1482/4885TAS1R3 992/4885 |
| US-20160158207-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | EP300, HDAC1, HDAC10 | GRN 1643/4885SORT1 2654/4885TAS1R3 3503/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.